Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISA 2022 | An insight into organ dysfunction and damage in AL amyloidosis

Stefano Ricagno • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Stefano Ricagno, PhD, University of Milan, Milan, Italy, briefly explains mechanisms of organ dysfunction and damage in AL amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

More from Stefano Ricagno

ISA session highlights: basic research on light chains & cardiotoxicity in amyloidosis
1:56
ISA session highlights: basic research on light chains & cardiotoxicity in amyloidosis
Stefano Ricagno • 6 Sep 2022
The role of protein dynamics and proteolysis in light chain amyloid aggregation
2:51
The role of protein dynamics and proteolysis in light chain amyloid aggregation
Stefano Ricagno • 6 Sep 2022
What is currently known about AL amyloidosis with cardiac involvement?
1:18
What is currently known about AL amyloidosis with cardiac involvement?
Stefano Ricagno • 6 Sep 2022

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Stefano Ricagno • 7 Dec 2025
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Stefano Ricagno • 5 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Stefano Ricagno • 8 Dec 2025
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
3:45
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
Stefano Ricagno • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals